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Objective: To determine the incidence of Chlamydia pneumoniae respiratory tract infection in HIV-positive or AIDS
patients.
Methods: Serum samples from 82 HIV-positive patients with fever and respiratory symptoms were evaluated using
microimmunofluorescence assay to detect C. pneumoniae-specific IgG and IgM antibodies.
Results: Twenty patients were found to have IgG antibodies to C. pneumoniae at titers ranging between 1: 16 and
1: 1024. Seven of the patients had evidence of acute C. pneumoniae infection (a fourfold rise in the titer of IgG antibody,
or a single IgG titer of ~1 :512, or a single IgM titer ~1: 16). Five were diagnosed as having pneumonia and two bronchitis.
No co-infection with other respiratory tract pathogens was found.
Conclusions: Results of this study indicate that C. pneumoniae may playa role in the etiology of respiratory tract
infections in HIV-positive patients; this fact should affect empirical antibiotic prescription.
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INTRODUCTION
Chlamydia pneumoniae represents a new addition to
the list of microbial pathogens. This microorganism
causes human respiratory infections including pneu-
monia, bronchitis and pharyngitis [1]. In addition,
chronic C. pneumoniae infection may be associated
with both chronic ischemic heart disease and acute
myocardial infarction [2J. Meningoencephalitis, the
Guillain-Barre syndrome, arthritis and erythema
nodosum have also been associated with C. pneumoniae
infection [3-6]. Serologic studies indicate that C.
pneumoniae is one of the most widespread infectious
agents, and epidemiologic studies have indicated a
worldwide distribution of this microorganism [7].
Pneumonia is a major problem among patients
with AIDS [8J. Therefore, it seemed reasonable to test
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AIDS patients with pneumonia for the presence of
C. pneumoniae infection. In fact, an outbreak of C.
pneumoniae infection has been reported in a group of 15
of26 former injection-drug users living together in the
community [9]. There have been two further reports
of C. pneumoniae infection in HIV-positive subjects
[10,11]. In an effort to understand better the impor-
tance of C. pneumoniae infection in HIV-positive
patients in our area, we have analyzed serum samples
from HIV-positive and AIDS subjects since 1992 for
antibody by a microimmunofluorescence technique.
MATERIALS AND METHODS
Test population
The group ofpatients consisted of82 subjects (55 males
and 27 females) examined at the Clinic of Infectious
Disease, Policlinico, Bari, Italy. The age of the patients
ranged from 18 to 60 years, with a mean age of 32. All
patients were HIV seropositive, as detected by ELISA
and confirmed by immunoblotting. HIV-positive
subjects were classified according to the Center for
Disease Control criteria as IV B (5), IV C1(31), IV C2
(1), IV D (6); 39 were asymptomatic. A diagnosis of
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community-acquired pneumonia and/or bronchitis
was based on clinical signs and symptoms (fever, cough,
dyspnea, abnormal breathing sounds), and radiologic
findings. Routine blood tests, sputum and/or broncho-
alveolar lavage cultures and evaluation of Pneumocystis
carinii, cytomegalovirus (CMV) and Mycobacterium spp.
were also performed in symptomatic patients.
Sample collection
Peripheral blood samples were collected by antecubital
venepuncture. Serum samples were separated by centri-
fugation, aliquoted and stored at - 20°C before being
tested. Paired serum samples were obtained from 28
patients and single samples from the remaining 54
patients.
Serologic studies
Serologic testing for C. pneumoniae antibody in the
immunoglobulin G and M (IgG and IgM) classes
was performed by the microimmunofluorescence (MIF)
method. This method uses formalinized purified ele-
mentary bodies of C. pneumoniae strain TW-183 as
antigen (Washington Research Foundation, USA). The
antigen spots are placed on the microscope slide. For
IgG antibody measurements, twofold dilutions were
incubated at 37°C for 30 min with the antigen; slides
were washed and incubated with antihuman IgG
antibody conjugates (Fluoline-G, bioMerieux Italia;
Rome, Italy) for 30 min at 37°C. For IgM antibody
measurements, diluted sera were incubated overnight
at +4°C with the antigens; slides were washed and
incubated with antihuman IgM antibody conjugates
(Fluoline M; bioMerieux Italia, Rome, Italy) for 30
min at 37°C.
Positive IgM antibodies were confirmed after
absorption with rheumatoid factor (RF) absorbent
(bioMerieux Italia, Rome, Italy) to remove unspecific
reactivity. Serologic evidence ofacute infection with C.
pneumoniae was defined as a fourfold or greater rise in
the titer of IgG or IgM antibody, or a single IgM titer
of ;::: 1:16, or a single IgG titer of ;::: 512. Sera from
patients positive for C. pneumoniae were also tested
for total antibody to Chlamydia trachomatis and for
IgG antibody to Chlamydia psittaci by an indirect
immunofluorescence test (C. trachomatis spot IF;
bioMerieux Italia, Rome, Italy; C. psittaci spot IF,
bioMerieux Italia, Rome, Italy). Serum samples were
also tested for the presence of specific antibodies
to Mycoplasma pneumoniae (Mycoplasma pneumoniae
IgG, Mycoplasma pneumoniae IgM, Bayer Diagnostici,
Italy), and Legionella pneumophila (Legionella indirect
fluorescent test, Zeus Scientific Inc., Raritan, NJ,
USA). Serology for Coxiella burnetii and the most
common viruses was not routinely carried out.
RESULTS
A total of 82 HIV-positive patients observed over a
period of 4 years from October 1992 to September
1995 were tested, of whom 20 (24.4%) were found
positive for C. pneumoniae IgG at titers ranging
between 1: 16 and 1: 1024. Two of the patients had
Table 1 Data of AIDS patients with current C. pneumoniae infection
C. pneumoniae
serology
Risk factors CD4+ cell Site of radiographic
Patient Agelsex for HIV count Clinical diagnosis changes 19G 19M Treatment
40/M Heterosexual 9/mrn3 Bronchitis 1024 Neg. Ci, 1+A'
acquisition E
2 371M Drug user 16/mrn3 Pneumonia Interstitial right 512 Neg. E
Pleuritis middle lobe
3 381M Homosexual 321mrn3 Pneumonia Interstitial right 1024b Neg. E
acquisition Pleuritis, KS middle lobe 512'
4 191M Hemophilia 9/mm3 Pneumonia Interstitial left 16b Neg. E
lower lobe 128'
5 331M Drug user 7/mrn3 Bronchitis 512 Neg. SXT'
C
6 341M Drug user 27/mm3 Pneun10nia Alveolar and interstitial 128 64 C
right middle-basal lobe
7 36/F Heterosexual 65/rnm3 Pneumonia Alveolar right 16b Neg. l'
acquisition lower lobe 64' C
'Antibiotic therapy empirically based. b Acute serum. 'convalescent serum.
A= amikacin; C = clarithromycin; Ci = ciprofloxacin; E = erythromycin; 1= imipenem; SXT =sulfamethoxazole-trimethoprim;
KS=Kaposi's sarcoma.
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C. pneumoniae IgG antibody titers of 1: 1024, two had
titers of 1:512 and two had titers of 1:128. Titers of
1:64 were found in six of the patients. Low-level titers
of antibodies (1: 16 to 1: 32) were observed in eight of
the patients. These antibody levels represent the highest
titer obtained for each patient.
Seven of the patients with C. pneumoniae antibody
had evidence ofacute infection. One patient had a high
titer ofIgG antibody (1: 1024), two patients had an IgG
titer of 1:512, and one patient had IgG antibody levels
of 1: 1024 in the acute serum and 1: 512 in the
convalescent serum. In another two patients a fourfold
increase in IgG titer was observed (from 1: 16 to 1: 128
and from 1:16 to 1:64, respectively). Finally, one
patient had an IgM titer of 1:64 and an IgG titer of
1: 128. A summary of data from the seven patients with
current C. pneumoniae infection is provided in Table 1.
Five were diagnosed as having pneumonia and two
bronchitis. In three of the patients with current C.
pneumoniae infection, interstitial changes were observed.
Alveolar opacities in the right middle-basal lobe with
development of bilateral interstitial opacities were
observed in one case (patient 6) and in another case
alveolar opacities in the right lower lobe wete found
(patient 7). In two patients, pleural effusions which
complicated right middle lobe pneumonia were present.
No co-infection with cytomegalovirus, mycobac-
teria, P. carinii, L. pneumophila, Mycoplasma pneumoniae
and other common pathogens was found in these seven
patients. The possibility that the antibodies to C.
pneumoniae resulted from cross-reactivity with other
chlamydia was ruled out by testing sera positive for IgG
to C. pneumoniae also for antibodies to C. trachomatis
and C. psittaci. Antibodies against these microorganisms
were not detected.
Four patients received erythromycin 3 g/day for 14
days, and a favorable clinical response was observed in
three patients. One patient (patient 2) failed to respond
and died in respiratory failure. Three patients received
clarithromycin 1 g/day for 14 days; a favorable clinical
response was seen in two patients. Another patient
failed to respond and died (patient 6).
DISCUSSION
Pulmonary infection is the most commonly recognized
clinical problem in AIDS. More than 80% of the oppor-
tunistic infections seen in patients with AIDS involve
the lung; in fact, the lung is known to be susceptible to
infections or to other insults during times of immuno-
suppression [8,12]. C. pneumoniae is a newly recognized
third species of the genus Chlamydia [13]. Since C.
pneumoniae was first reported, several publications have
confirmed its importance as a new respiratory pathogen.
In fact, C. pneumoniae accounts for 10% of cases of
community-acquired pneumonia and there is evidence
that C. pneumoniae may also account for cases of noso-
comial pneumonia [14,15]. In our previous study, we
found that 13 of91 adult patients with respiratory tract
infection had serologic evidence of recent infection
with C. pneumoniae. The clinical picture was consistent
with asthmatic bronchitis in three patients, whilst
exacerbations of chronic obstructive pulmonary disease
were found in five subjects, and pneumonia was found
in the remaining five [16]. Serologic studies in several
countries have shown an antibody prevalence from 40%
to over 50%, suggesting that exposure to C. pneumoniae
IS very common.
Recently, studies on the incidence of C. pneu-
moniae infection in HIV-positive subjects have been
reported. Bronchoalveolar lavage specimens from HIV-
infected patients with pneumonia were examined by
culture for the presence of C. pneumoniae. Five of
50 (10%) specimens examined were positive for C.
pneumoniae, and four of these five specimens contained
other pulmonary pathogens (P. carinii in two cases and
Mycobacterium tuberculosis in another two). Four of
the five specimens were from patients with AIDS.
However, the role of C. pneumoniae in the pathologic
process remains unclear, because serologic data were
not available and because four of these patients recovered
with antimicrobial agents (such as pentamidine or
antimycobacterial agents) not effective against C. pneu-
moniae [10].
Another study reported that in an HIV-l-infected
population, C. pneumoniae seroprevalence was found to
be higher than in immunocompetent controls (26% in
HIV-positive children versus 11% in HIV-negative
children; 60% in HIV-positive drug users versus 40% in
HIV-negative drug users). The authors suggested that
HIV-infected subjects seem to be at higher risk of
developing C. pneumoniae infections and that immuno-
deficiency rather than lifestyle may be the risk factor
for C. pneumoniae infection [17]. In another study,
among 108 immunodeficient patients, 34% of whom
were HIV positive, C. pneumoniae DNA was demon-
strated in bronchoalveolar lavage fluid from 11 (1 %)
[18]. In addition, an outbreak of C. pneumoniae in-
fection in 26 former injection drug-users has been
reported in Italy by Blasi et al. [9]. Pneumonia was the
syndrome most frequently observed (in eight HIV-
positive and in three HIV-negative subjects) followed
by pharyngitis and flu-like syndrome.
We found current C. pneumoniae infection in 7
of 82 patients studied. In the remaining 13 patients,
antibodies were found at low titer, suggesting a
seroprevalence of 16% in this group of patients, lower
than that reported by Blasi et al. [17]. Patients with
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AIDS are at risk for infection with a wide range of
microorganisms. In fact, alteration of T-Iymphocyte
function by HIV increases host susceptibility to oppor-
tunistic infections caused by mycobacteria, viruses,
fungi and protozoa. Because HIV also alters B-
lymphocyte function, it may increase a patient's risk of
bacterial infection. Many of the clinical infections
observed in AIDS may be due to reactivation oflatent
infections acquired earlier in life.
Previously, studies showed that the prevalence of
antibody to C. trachomatis [19] and C. pneumoniae [20]
in HIV-positive subjects is higher than in HIV-negative
subjects and controls. It is well known that the humoral
response, as well as the cell-mediated immune response,
plays a role in maintaining an effective defense against
C. trachomatis [21], whereas few data are available on
the interaction between C. pneumoniae and the immune
system [22]. It appears that, among bacterial infections
that may be reactivated when the cellular immune
system is destroyed by HIV, chlamydia may playa role.
In fact, C. pneumoniae infections in HIV-positive
patients have been reported [9-11]. On the other hand,
Moncada et al. have isolated C. trachomatis from brush
biopsies and lung lavage in only 3 of 263 individuals
with AIDS (0.5%), suggesting that this microorganism
is not an important respiratory tract pathogen in this
population [23].
All these findings should alert bacteriology labora-
tories and clinicians to investigate for the presence of
C. pneumoniae infections in HIV-positive patients with
lower respiratory tract infections. Furthermore, the
realization that C. pneumoniae may be an etiologic agent
of pneumonia and bronchitis in these patients should
affect empirical antibiotic prescription.
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